Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy

J Orthop Sci. 2018 Mar;23(2):389-393. doi: 10.1016/j.jos.2017.10.012. Epub 2017 Nov 14.

Abstract

Background: Botulinum toxin A treatment involves injecting botulinum toxin A to relax muscle spasticity. Using ultrasonography, this study examined changes in the muscle architecture before and after treatment to evaluate the influence of botulinum toxin A injection on muscles.

Methods: The participants included 18 children (mean age, 6.2 years) with cerebral palsy who were treated with botulinum toxin A for lower extremity spasticity and 27 healthy children (mean age, 6.4 years) as a control group. In all cases, botulinum toxin A was injected into the gastrocnemius muscle. The muscle length, muscle width, and pennation angle (which indicates the degree of muscle fiber tone), were measured using B-mode ultrasonography before and 12 weeks after injection.

Results: The muscle length and muscle width were shorter in the cerebral palsy group than in the control group. The pennation angle in the cerebral palsy group significantly decreased after injection from 28.2 ± 3.6° to 25.8 ± 2.5° in the resting position of the ankle and from 18.6 ± 2.8° to 15.9 ± 1.7° in the maximum dorsiflexion position of the ankle. In the control group, the pennation angle was 25.9 ± 3.2° in the resting position of the ankle and 15.1 ± 2.5° in the maximum dorsiflexion position of the ankle. The rate of increase of fascicle length during passive movement from the resting position of the ankle to the maximum dorsiflexion position was 143.9% in the cerebral palsy group, which was significantly less than the value of 157.7% in the control group. After botulinum toxin A treatment, the rate of increase of fascicle length in the cerebral palsy group increased to 155.1%.

Conclusions: The decrease in the pennation angle after botulinum toxin A treatment is considered to be the result of a reduction of spasticity and subsequent structural changes in flaccid muscle fibers.

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Case-Control Studies
  • Cerebral Palsy / complications
  • Cerebral Palsy / diagnosis
  • Cerebral Palsy / drug therapy*
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intramuscular
  • Lower Extremity
  • Male
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology
  • Muscle Spasticity / physiopathology
  • Muscle, Skeletal / diagnostic imaging*
  • Muscle, Skeletal / drug effects*
  • Reference Values
  • Retrospective Studies
  • Risk Assessment
  • Statistics, Nonparametric
  • Treatment Outcome
  • Ultrasonography, Doppler / methods

Substances

  • Botulinum Toxins, Type A